MHMichael Holinstat

Michael Holinstat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael Holinstat has a total of 321 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Platelet Reactivity and Sex Differences: Clinical Implications for Women

    by Anu Aggarwal, Tessa J. Barrett, Puja K. Mehta, Michael C. Honigberg, Judith M.E.M. Cosemans, Wendy A. Goodman, Niti R. Aggarwal, Michael Holinstat, Leslie Cho, Scott J. Cameron

    Platelets are central to hemostasis and thrombosis. Excessive platelet activation contributes to arterial thrombotic events, including myocardial infarction, ischemic stroke, and complications of peripheral artery disease, whereas excessive platelet inhibition increases bleeding risk. Antiplatelet therapy remains a cornerstone of secondary prevention in atherosclerotic and thrombotic cardiovascular diseases, yet current treatment paradigms do not fully account for biological heterogeneity in platelet function, including differences related to sex, age, hormonal status, and disease context. This state-of-the-art review examines current antiplatelet strategies, fundamental mechanisms of signal transduction, clinical indications, and limitations of preclinical and clinical studies, with a focus on sex-specific considerations and opportunities for personalized antiplatelet therapy. Aspirin and P2Y 12 receptor antagonists are widely used for secondary prevention. However, women have been underrepresented in many pivotal clinical trials, limiting the precision of sex-specific estimates of efficacy and bleeding risk. In parallel, commonly used preclinical models often fail to recapitulate the physiological conditions in which platelets interact with the vasculature, leukocytes, and soluble factors. Emerging therapeutic approaches seek to refine platelet inhibition by targeting pathways that reduce thrombotic risk while preserving hemostasis. Advancing antiplatelet therapy will require integration of mechanistic platelet biology with diverse clinical trial populations, standardized platelet phenotyping, and disease-specific approaches that account for how platelet function is altered across health and vascular disease.

  • Open Access

    Self-cleavage-dependent and -independent functions of Adgrg1/Gpr56 in mice

    by Frank E. Kwarcinski, Tyler F. Bernadyn, James P. Teuber, Mariane Nascimento, Ingrid Bergin, Tingzhen Shen, Riya Gandhi, Xinyi Lu, Matthew J. Brody, Michael Holinstat, et al.

    Adhesion G protein–coupled receptors (AGPCRs) regulate essential physiological processes through interactions between their ectodomains and adjacent cell surface proteins or extracellular matrix components (ECM). AGPCRs distinctively arrive at the plasma membrane as self-cleaved holoreceptors with noncovalently associated N-terminal (NTF) and C-terminal fragments (CTF). Canonical AGPCR signaling proceeds in three sequential steps; NTF adhesive domains bind to ligands, extracellular shear force mediates NTF and CTF dissociation, a tethered peptide agonist (TA) is exposed and binds to the CTF orthosteric site to stabilize the active state receptor. Depending on the cellular context, both autoproteolysis-deficient and perhaps, a few cleavage-capable AGPCRs may be activated without NTF dissociation or the action of the TA. To discriminate the functional consequences of these signaling modes in vivo, we created a cleavage-deficient, Gpr56 H381S knock-in mouse and investigated five distinct defective phenotypes of Gpr56 knockout mice. One prominent phenotype, brain malformation that parallels human bilateral frontoparietal polymicrogyria (BFPP) disease, is characterized by dysplasia of the cortex and cerebellum and neuron heterotopia. Brain histology analyses confirmed that Gpr56 H381S mice had comparable cerebellar structural irregularities as Gpr56 knockout mice, indicating that TA agonism is indispensable for proper cerebellar lobule formation and neuronal migration. TA-dependent signaling was also required for male mouse fertility, but not for adult cardiomyocyte homeostatic functions, platelet-dependent hemostasis, or axon myelination in the central nervous system. These findings indicate that GPR56 has multiple modes of activation and that these signaling outcomes are likely driven by NTF interactions with specific ligands including collagen and transglutaminase-2.

  • Open Access

    VLX-1005, but not argatroban, prevents ITAM-mediated platelet activation and heparin-induced thrombocytopenia

    by Adriana Yamaguchi, Victoria Putzbach, Reheman Adili, Sophia Lazar, Livia Stanger, Devin Gilmore, David J. Maloney, Steven E. McKenzie, James V. Michael, Michael Holinstat

  • Activation of GPR97/ADGRG3 by its tethered agonist, but not by beclomethasone, induces neutrophil polarization and migration

    by Tyler Bernadyn, Frank Kwarcinski, Naincy Chandan, Riya Gandhi, Yuling Feng, Michael Holinstat, Carole A. Parent, Alan V. Smrcka, Gregory G. Tall

    Most adhesion G protein–coupled receptors (AGPCRs) are activated by the intramolecular binding of a tethered agonist, which is exposed by shear force–induced dissociation of the N- and C-terminal fragments of AGPCRs. The decrypted tethered agonist binds to its orthosteric site in the C-terminal fragment to stabilize the active state of the AGPCR. Corticosteroids have been proposed to be orthosteric agonists for GPR97/ADGRG3. Here, we showed that GPR97/ADGRG3 is activated by the canonical tethered agonist mechanism. In cell-based luciferase reporter assays and receptor/G protein reconstitution assays, GPR97/ADGRG3 was stimulated by agonist peptidomimetics and by 3-acetoxydihydrodeoxygeduin (3-α-DOG), a partial agonist of the ADGRG subfamily, but not by corticosteroids. We showed that GPR97 was a promiscuous AGPCR that coupled to G 13 , G s , and G i but not to G q . GPR97 is abundant in neutrophils, which undergo cell shape changes and polarization and migrate upon activation. GPR97 activation by tethered agonist peptidomimetics or 3-α-DOG robustly stimulated cAMP production, polarization, and chemotaxis in human and mouse neutrophils. These effects in mouse neutrophils required GPR97 and were not mimicked by the corticosteroid beclomethasone in either cell type. Together, our results demonstrate that GPR97/ADGRG3 uses a tethered agonist mechanism to activate G protein signaling and induce neutrophil polarization and migration.


  • Open Access

    ER-associated degradation pathway protein SEL1L plays an evolutionarily conserved role in platelet adhesion

    by Anna R. Dahlgren, Francesca Careddu, Jeffrey W. Norris, Christian A. Di Buduo, Livia Stanger, Reheman Adili, Erin M. Kropp, Qing Li, Michael Holinstat, Ida Biunno, et al.

    SEL1L is a well-known protein in the ER-associated degradation (ERAD) pathway. While it is known to be expressed in platelets, SEL1L has never been shown to play an active role. Here, we present evidence that SEL1L regulates platelet function. We first identified SEL1L through the study of Atypical Equine Thrombasthenia (AET), an autosomal recessive platelet disorder found in thoroughbred horses. A missense variant in SEL1L (c.1810A>G p.Ile604Val) was found in AET-affected horses, which we show is associated with decreased protein expression. SEL1L is intracellular in equine platelets and localizes to the surface upon activation with thrombin. Platelets from homozygous horses exhibited substantially decreased spreading on immobilized collagen. Human megakaryocytes were found to have 2 SEL1L protein isoforms that increase in expression during megakaryopoiesis, although only 1 isoform was delivered to mature platelets. Studies using inducible mouse and constitutive zebrafish KOs demonstrated that SEL1L is necessary for efficient platelet or thrombocyte (fish equivalent) adhesion to sites of endothelial injury. These data reveal a previously undescribed and conserved role for the ERAD pathway in the etiology of AET and platelet function, and GWAS data suggest that it may play a role in human platelet disorders as well.


  • Open Access

    13-HODE and 13-HOTrE, Present in the Traditional Chinese Medicine Herbal Extract di gu pi, Selectively Inhibit Platelet Function

    by Dylan Simpson, Eliana Botta, Pooja Yalavarthi, Yein Ji, Krista Goerger, Paul Houston, Sky Kareht, Drewv Desai, Daniela Bolaños, Theodore R. Holman, et al.

    Background: Platelet hyperreactivity contributes to occlusive thrombus formation in vessels, precipitating acute cardiovascular events such as myocardial infarction and stroke. Traditional Chinese Medicine (TCM) has been used for centuries, and numerous TCM herbs have been reported to exert anti-inflammatory and anticoagulant effects. Objectives: We sought to identify key compounds within the TCM-derived herbal extracts that regulate platelet activity. Methods: Crude and fractioned herbal extracts were screened for their ability to inhibit platelet activation in response to multiple agonists. Platelet aggregation and flow cytometry were used to assess the potency and selectivity of the compounds within the extracts. Results: Three extracts, di gu pi (DGP), san qi (SQ), and zi cao (ZC), demonstrated inhibitory activity and were subsequently fractionated. Fractions derived from DGP, the root bark of Lycium chinense, inhibited platelet aggregation and suppressed integrin activation and granule secretion downstream of collagen receptor signaling. Further analysis identified the oxidized lipids 9(S)-hydroxy-9Z,11E-octadecadienoic acid (9-HODE), 13(S)-HODE, and 13(S)-hydroxy-9Z,11E,15Z-octadecatrienoic acid (13-HOTrE) as constituents of the bioactive fractions. Both 13-HODE and 13-HOTrE selectively inhibited collagen-mediated platelet aggregation without affecting thrombin-induced activation. Conclusions: Collectively, these findings identify oxylipins in TCM as promising candidates for the development of antiplatelet therapies targeting platelet activity and thrombosis. These oxylipins may represent novel approaches for thrombosis and have high therapeutic potential for development as next-generation antiplatelet drugs.

  • Open Access

    Phospholipase A2 products influence the antiplatelet functions of synthetic high-density lipoproteins

    by Antonela Rodriguez, Minzhi Yu, Jingyao Gan, May Thazin Phoo, Alankrita Rani, Gunther Marsche, Yanhong Guo, Michael Holinstat, Anna Schwendeman

  • Open Access

    Novel histone deacetylase inhibitor, CS014, attenuates in vivo thrombosis while maintaining hemostasis

    by Livia Stanger, Pooja Yalavarthi, Reheman Adili, Devin Gilmore, Timothy Hoang, Avery Campbell, Paul Krenik, David Gustafsson, Jan Fryklund, Tomas Fex, et al.

  • Novel Approaches to Antiplatelet Therapy

    by Krista Goerger, Michael Holinstat

  • Open Access

    GPR97/ADGRG3 is activated by its tethered peptide agonist and not by steroids to induce neutrophil polarization and migration

    by Tyler Bernadyn, Frank Kwarcinski, Naincy Chandan, Riya Gandhi, Yuling Feng, Michael Holinstat, Carole A. Parent, Alan V. Smrcka, Gregory G. Tall

    Most adhesion G protein coupled receptors (AGPCRs) are activated by intramolecular binding of a tethered-peptide agonist (TA). Shear force-induced dissociation of the AGPCR N-terminal fragment (NTF) and C-terminal fragment (CTF) exposes the TA. The decrypted TA binds rapidly to its orthosteric site within the CTF to stabilize the active state of the AGPCR. Corticosteroids were previously proposed to be agonists for GPR97/ADGRG3. Later, other steroids and androgens were purported to be selective agonists of additional AGPCRs. Here, we demonstrate that GPR97/ADGRG3 is activated by dissociation of its NTF/CTF and follows the TA mechanism. TA peptidomimetics and the ADGRG subfamily partial agonist 3-acetoxydihydrodeoxygeduin (3-α-DOG), but not corticoids, stimulated GPR97/ADGRG3 in cell-based luciferase reporter assays and receptor/G protein reconstitution assays. GPR97 was defined as a promiscuous AGPCR that couples to G13, Gs and Gi, but not Gq. GPR97 is highly expressed in human polymorphonuclear neutrophils (hPMNs). Neutrophils undergo actin polymerization-induced cell shape changes and polarization and migrate upon activation. We found that GPR97 activation via TA peptidomimetics or 3-α-DOG robustly stimulated hPMN and mouse bone-marrow neutrophil (mBMN) polarization. Furthermore, GPR97 TA peptidomimetics and 3-α-DOG, but not beclomethasone, induced hPMN and mBMN chemotaxis. Together, our results demonstrate that GPR97/ADGRG3 utilizes a tethered agonist mechanism to activate G protein signaling and induce neutrophil polarization and migration. One Sentence Summary: GPR97/ADGRG3 tethered agonism regulates G protein signaling in neutrophils.